148 related articles for article (PubMed ID: 21636270)
1. Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.
Staben ST; Siu M; Goldsmith R; Olivero AG; Do S; Burdick DJ; Heffron TP; Dotson J; Sutherlin DP; Zhu BY; Tsui V; Le H; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Sideris S; Wiesmann C; Wu P
Bioorg Med Chem Lett; 2011 Jul; 21(13):4054-8. PubMed ID: 21636270
[TBL] [Abstract][Full Text] [Related]
2. Cis-amide isosteric replacement in thienobenzoxepin inhibitors of PI3-kinase.
Staben ST; Blaquiere N; Tsui V; Kolesnikov A; Do S; Bradley EK; Dotson J; Goldsmith R; Heffron TP; Lesnick J; Lewis C; Murray J; Nonomiya J; Olivero AG; Pang J; Rouge L; Salphati L; Wei B; Wiesmann C; Wu P
Bioorg Med Chem Lett; 2013 Feb; 23(3):897-901. PubMed ID: 23265894
[TBL] [Abstract][Full Text] [Related]
3. Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.
Staben ST; Ndubaku C; Blaquiere N; Belvin M; Bull RJ; Dudley D; Edgar K; Gray D; Heald R; Heffron TP; Jones GE; Jones M; Kolesnikov A; Lee L; Lesnick J; Lewis C; Murray J; McLean NJ; Nonomiya J; Olivero AG; Ord R; Pang J; Price S; Prior WW; Rouge L; Salphati L; Sampath D; Wallin J; Wang L; Wei B; Weismann C; Wu P
Bioorg Med Chem Lett; 2013 May; 23(9):2606-13. PubMed ID: 23540645
[TBL] [Abstract][Full Text] [Related]
4. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
[TBL] [Abstract][Full Text] [Related]
5. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
[TBL] [Abstract][Full Text] [Related]
6. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
Sutherlin DP; Sampath D; Berry M; Castanedo G; Chang Z; Chuckowree I; Dotson J; Folkes A; Friedman L; Goldsmith R; Heffron T; Lee L; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Olivero A; Pang J; Prior WW; Salphati L; Sideris S; Tian Q; Tsui V; Wan NC; Wang S; Wiesmann C; Wong S; Zhu BY
J Med Chem; 2010 Feb; 53(3):1086-97. PubMed ID: 20050669
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).
Moffett K; Konteatis Z; Nguyen D; Shetty R; Ludington J; Fujimoto T; Lee KJ; Chai X; Namboodiri H; Karpusas M; Dorsey B; Guarnieri F; Bukhtiyarova M; Springman E; Michelotti E
Bioorg Med Chem Lett; 2011 Dec; 21(23):7155-65. PubMed ID: 22014550
[TBL] [Abstract][Full Text] [Related]
8. Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.
Heffron TP; Wei B; Olivero A; Staben ST; Tsui V; Do S; Dotson J; Folkes AJ; Goldsmith P; Goldsmith R; Gunzner J; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Shuttleworth S; Sutherlin DP; Wan NC; Wang S; Wiesmann C; Zhu BY
J Med Chem; 2011 Nov; 54(22):7815-33. PubMed ID: 21985639
[TBL] [Abstract][Full Text] [Related]
9. Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibitors: capturing interactions with Asp48.
Wan ZK; Lee J; Xu W; Erbe DV; Joseph-McCarthy D; Follows BC; Zhang YL
Bioorg Med Chem Lett; 2006 Sep; 16(18):4941-5. PubMed ID: 16806920
[TBL] [Abstract][Full Text] [Related]
10. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
[TBL] [Abstract][Full Text] [Related]
11. Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors.
Moretto AF; Kirincich SJ; Xu WX; Smith MJ; Wan ZK; Wilson DP; Follows BC; Binnun E; Joseph-McCarthy D; Foreman K; Erbe DV; Zhang YL; Tam SK; Tam SY; Lee J
Bioorg Med Chem; 2006 Apr; 14(7):2162-77. PubMed ID: 16303309
[TBL] [Abstract][Full Text] [Related]
12. Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.
Pecchi S; Ni ZJ; Han W; Smith A; Lan J; Burger M; Merritt H; Wiesmann M; Chan J; Kaufman S; Knapp MS; Janssen J; Huh K; Voliva CF
Bioorg Med Chem Lett; 2013 Aug; 23(16):4652-6. PubMed ID: 23820386
[TBL] [Abstract][Full Text] [Related]
13. Lead optimization of a dihydropyrrolopyrimidine inhibitor against phosphoinositide 3-kinase (PI3K) to improve the phenol glucuronic acid conjugation.
Kawada H; Ebiike H; Tsukazaki M; Nakamura M; Morikami K; Yoshinari K; Yoshida M; Ogawa K; Shimma N; Tsukuda T; Ohwada J
Bioorg Med Chem Lett; 2013 Feb; 23(3):673-8. PubMed ID: 23265889
[TBL] [Abstract][Full Text] [Related]
14. Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies.
Wang X; Lin J; Chen Y; Zhong W; Zhao G; Liu H; Li S; Wang L; Li S
Bioorg Med Chem; 2009 Mar; 17(5):1898-904. PubMed ID: 19223187
[TBL] [Abstract][Full Text] [Related]
15. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.
Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
Lin X; Murray JM; Rico AC; Wang MX; Chu DT; Zhou Y; Del Rosario M; Kaufman S; Ma S; Fang E; Crawford K; Jefferson AB
Bioorg Med Chem Lett; 2006 Aug; 16(16):4163-8. PubMed ID: 16765046
[TBL] [Abstract][Full Text] [Related]
17. 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.
Soth M; Abbot S; Abubakari A; Arora N; Arzeno H; Billedeau R; Dewdney N; Durkin K; Frauchiger S; Ghate M; Goldstein DM; Hill RJ; Kuglstatter A; Li F; Loe B; McCaleb K; McIntosh J; Papp E; Park J; Stahl M; Sung ML; Suttman R; Swinney DC; Weller P; Wong B; Zecic H; Gabriel T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3452-6. PubMed ID: 21515047
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1.
Hornberger KR; Berger DM; Crew AP; Dong H; Kleinberg A; Li AH; Medeiros MR; Mulvihill MJ; Siu K; Tarrant J; Wang J; Weng F; Wilde VL; Albertella M; Bittner M; Cooke A; Gray MJ; Maresca P; May E; Meyn P; Peick W; Romashko D; Tanowitz M; Tokar B
Bioorg Med Chem Lett; 2013 Aug; 23(16):4517-22. PubMed ID: 23850198
[TBL] [Abstract][Full Text] [Related]
19. Thiophene substituted acylguanidines as BACE1 inhibitors.
Fobare WF; Solvibile WR; Robichaud AJ; Malamas MS; Manas E; Turner J; Hu Y; Wagner E; Chopra R; Cowling R; Jin G; Bard J
Bioorg Med Chem Lett; 2007 Oct; 17(19):5353-6. PubMed ID: 17761418
[TBL] [Abstract][Full Text] [Related]
20. Fused thiophene derivatives as MEK inhibitors.
Laing VE; Brookings DC; Carbery RJ; Simorte JG; Hutchings MC; Langham BJ; Lowe MA; Allen RA; Fetterman JR; Turner J; Meier C; Kennedy J; Merriman M
Bioorg Med Chem Lett; 2012 Jan; 22(1):472-5. PubMed ID: 22119475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
